Discovering an Invisible Layer in Retina and Its Ties to AMD
About the Research Project
Program
Award Type
New Investigator Grant
Award Amount
$449,323
Active Dates
July 01, 2022 - June 30, 2025
Grant ID
M2022009N
Mentor(s)
Brandon Lujan, MD, Oregon Health & Science University
Goals
To develop a retinal imaging device called volumetric directional Optical Coherence Tomography (VD-OCT), which will allow us to visualize a normally invisible retinal layer and study its role in age-related macular degeneration (AMD).
Summary
Aim 1: Develop an advanced retinal imaging device for measuring the true thickness of the outer nuclear layer (ONL) in the entire macular region, by: 1. Improving imaging speed, 2. Developing novel scanning patterns, 3. Training artificial intelligence to fully automate the imaging acquisition. Aim 2: Pilot imaging studies using the VD-OCT prototypes. First step: a pilot validation study on normal subjects. The second step is a short-term prospective observational study to measure the thickness of ONL in intermediate-stage dry-AMD patients and healthy age-matched control subjects.
Unique and Innovative
Our proposed volumetric directional optical coherence tomography (OCT) can visualize a retinal layer (Henle’s fiber layer) that is invisible in the current OCT retinal imaging devices. This discovery leads to the precise measurement of the true outer nuclear layer thickness, which is an important biomarker for photoreceptor health. We will also leverage the recent development in laser technology to significantly increase imaging speed and artificial intelligence to automate the imaging procedure which could significantly improve the clinical utility.
Foreseeable Benefits
Our VD-OCT will provide an accurate measurement of ONL thickness. An improved understanding of photoreceptor cell loss around the drusen and in the wider macula will allow new insight into AMD progression and provide precise imaging biomarkers for AMD clinical trials. In this study, OCT biomarkers reflecting photoreceptor degeneration will allow earlier identification and quantification of progression to advanced AMD. Finally, in the context of current and future gene- and cell-based therapies, precise measurements of the ONL may prove to be an important quantitative imaging biomarker of regeneration.
Grants
Related Grants
Macular Degeneration Research
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Macular Degeneration Research
Understanding Early Molecular Events in Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Sandeep Moothedath Subrahmanian, PhD
Understanding Early Molecular Events in Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Sandeep Moothedath Subrahmanian, PhD
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD